Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis.
Phase of Trial: Phase I/II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer; Carcinomatous meningitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms HIT
- 07 Jun 2017 Biomarkers information updated
- 05 Feb 2016 Planned End Date changed from 1 Jun 2017 to 1 May 2019 as per ClinicalTrials.gov record.
- 05 Feb 2016 Planned primary completion date changed from 1 May 2015 to 1 Sep 2017 as per ClinicalTrials.gov record.